Â鶹Éç

It has been less than a year since listed its IPO, but the activity has been quite hot, particularly since the top of the year. With , there certainly appears to be a lot of interest in the budding clinical-stage biopharmaceutical company.

But only a few days before MLYS officially goes public (on February 14, 2023), they announced an upsized public option to encourage more early investors and secure a little more liquidity to support early development.Sure enough, the Feb 10 upgrade helped to as much as $21.98 before setting down to its current price of $18.44 per share.

Funding Boost Could Imply Greater Promise

Not long after closed its , Mineralys Therapeutics Inc announced they would do the same.Scheduled for listing on the Nasdaq index under the symbol MYLS, this will mark the second biotech to raise more than $100 million in funding in just a month.It also marks the first time the Nasdaq a seen a pair like this since May, a hopeful sign of more pending growth in the biotech sector.

It is a bid that will certainly provide more opportunity for investors to get in on the ground floor, especially since the higher valuation will give them a better position against older and larger entities, like .With a goal to sell 10 million shares in the initial period–at $16 a piece–the addition of 20% more shares could boost valuation to upwards of $192 million (based on the sale of 12 million shares ).

Of course, there could be even more value if they also manage to sell their scheduled 1.8 million over-allotment as well.But even if their surplus sale is weak, the IPO will give Mineralys strong liquidity moving forward. MLYS currently has a market capitalization value of $683.32 million.With a baseline cash value of $120.95 million and more than $158 million in other assets, MLYS will likely be heading to the public market with a of at least $721 million.

Strong Product Results Suggest Future Growth

Speaking of moving forward, the Radnor, PA-based firm recently completed a to evaluate the safety and efficacy of their current lead pipeline candidate, an Also referred to as MLS-101, the aim with this drug is as an add-on for patients living with uncontrolled or resistant hypertension (uHTN/rHTN).In addition, they expect to start another phase 2 trial for the same drug to treat uHTN and rHTN among the chronic kidney disease population. This will come around the middle of 2023.

The top-line data for both of these studies are expected in early 2024.These results will establish a foundation for phase 3 programs and, hopefully, eventually head to market.Mineralys will need that, as the IPO funding will likely run out by then, so a new income stream will be crucial.

Singular Product Focus Could Help Mineralys Jump Ahead

This is particularly important because Mineralys from for an initial $1 million with a contract that includes up to $9 million in additional development milestone payments and another $155 million in commercial milestone payments. Mineralys scooped up this drug candidate for its ability to inhibit an enzyme that can effectively lower blood pressure.

It’s a novel concept that is also on the radar of several other companies.As mentioned, AstraZeneca is a direct competitor in this field, having peer for $1.8 billion.However. CinCor’s candidate last year, so the lane could be wide open for Mineralys to go head-to-head with AstraZeneca instead.

MLYS share value currently , representing a 15% premium on the initial $16 price.With their singularly-focused pipeline–and Cincor’s recent trial miss–MLYS could emerge from this initial public offering as the clear front-runner in its market.

That, of course, could make them a solid long-term investment, particularly since its current share value is highly competitive.AZN, for example, currently lists at . That is a 370% premium over MLYS, which could make MLYS a smarter buy on a long-term basis.